Christina Marinaro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christina Marinaro has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Suzie Chen
Rutgers University
3 shared publications - Allen B. Reitz
Fox Chase Therapeutics Discovery Inc
2 shared publications - Andrew Zloza
Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA
2 shared publications - Ann W. Silk
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
2 shared publications - Anna Chaly
Fox Chase Therapeutics Discovery, Doylestown, Pennsylvania, USA
2 shared publications - Anna Fateeva
Susan Lehman Cullman Laboratory for Cancer Research, Rutgers University, Piscataway, NJ 08854, USA
2 shared publications
Latest Publications
- Open Access
- 16 September 2024
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 38 (1)
An In Vivo Study of LNS8801, a GPER Agonist, in a Spontaneous Melanoma‐Prone Mouse Model, TGS
Melanoma is the most aggressive and deadly form of skin cancer that arises from the transformation of melanocytes, the pigment producing cells of the skin. In the year 2024 there will be approximately 10,000 new cases of melanoma diagnosed and approximately 8,000 deaths attributed to melanoma in the United States. In this study we treated a group of male and female transgenic mice that spontaneously develop metastatic melanoma, TGS, with a G‐protein‐coupled estrogen receptor agonist LNS8801 to assess the efficacy on disease progression. A second group of male and female TGS mice was also exposed to UVB irradiation to mimic exposure to sunlight. Over the course of the 32‐week experiment, visible images were taken by the small animal imaging IVIS system to track tumor progression, and blood and tissue samples were collected for molecular analyses. Results showed that sex‐biased effects were observed in the efficacy of LNS8801 and that LNS8801 shows a UV‐protective influence in both male and female TGS mice.
- 16 September 2024
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 38 (1)
Open AccessAn In Vivo Study of LNS8801, a GPER Agonist, in a Spontaneous Melanoma‐Prone Mouse Model, TGS
Melanoma is the most aggressive and deadly form of skin cancer that arises from the transformation of melanocytes, the pigment producing cells of the skin. In the year 2024 there will be approximately 10,000 new cases of melanoma diagnosed and approximately 8,000 deaths attributed to melanoma in the United States. In this study we treated a group of male and female transgenic mice that spontaneously develop metastatic melanoma, TGS, with a G‐protein‐coupled estrogen receptor agonist LNS8801 to assess the efficacy on disease progression. A second group of male and female TGS mice was also exposed to UVB irradiation to mimic exposure to sunlight. Over the course of the 32‐week experiment, visible images were taken by the small animal imaging IVIS system to track tumor progression, and blood and tissue samples were collected for molecular analyses. Results showed that sex‐biased effects were observed in the efficacy of LNS8801 and that LNS8801 shows a UV‐protective influence in both male and female TGS mice.
- Open Access
- 19 January 2024
- Published by Elsevier in JID Innovations
- Vol. 4 (2) , 100262
Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model
- 19 January 2024
- Published by Elsevier in JID Innovations
- Vol. 4 (2) , 100262
Open AccessAssessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model
- Open Access
- 29 March 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (10) , 2007-2018.e6
A Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy Study
- 29 March 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (10) , 2007-2018.e6
Open AccessA Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy Study